In Brief: Pharmacia & Upjohn
Pharmacia & Upjohn: Reorganization of R&D will more tightly focus resources on defined steps of product development, with three areas of "functional focus": preclinical, clinical and product development. The company recently began centralizing its global pharmaceutical business ("The Pink Sheet" July 7, p. 5). As part of the reorganization, five R&D executives are appointed to new duties. Former Pharma Product Center Sweden VP-Research Les Hudson, PhD, 53, is named divisional senior VP-worldwide discovery research. Per Olof Andersson, MD/PhD, 44, previously VP-development at the U.S. Pharma Product Center, will be divisional senior VP-exploratory development; his U.S. PPC colleague, former VP and Project Leader for Development John Landis, PhD, 44, is appointed divisional senior VP-preclinical development. Former Senior VP-Worldwide Product Development Birgit Stattin, 48, is named corporate senior VP-product development. Mike Tansey, MD/PhD, 49, will continue as chief medical officer and will add the title of divisional senior VP-clinical development...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth